Ignite Creation Date:
2024-05-05 @ 5:09 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00395850
Status:
COMPLETED
Last Update Posted:
2013-11-13
First Post:
2006-11-02
Brief Title:
Disulfiram for Cocaine Abuse
Sponsor:
University of Arkansas
Organization:
University of Arkansas
Study Overview
Official Title:
Disulfiram for Cocaine Abuse
Status:
COMPLETED
Status Verified Date:
2013-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study examines the influence of dopamine beta-hydroxylase enzyme activity on the clinical efficacy of the novel pharmacotherapy disulfiram for treating cocaine dependence in cocaine-dependent patients some of whom are opioid dependent and maintained on an FDA-approved opioid agonist Cocaine dependence as well as co-morbid cocaine and opioid-dependence is associated with more public health issues and poorer treatment prognosis when admitted to methadone maintenance Yet no effective pharmacotherapies have been developed to treat cocaine dependence to date One novel pharmacotherapy disulfiram has shown some promise as a treatment for this disorder in several clinical trials at a dose of 250 mgday or more eg Carroll et al 1998 2004 This 14-week randomized double blind clinical trial will provide treatment for up to160 cocaine-dependent individuals aged 18-65 years Participants who are opioid dependent will be stabilized on methadone maintenance during the first 2 weeks and baseline cocaine use will be assessed participants will be stratified by DBH genotype and randomly assigned to receive disulfiram at either 0 250 375 or 500 mgday During induction onto methadone for opioid dependent individuals participants are administered increasing doses of methadone on a daily basis until maintenance doses are attained At the beginning of week 3 participants receive methadone if relevant plus disulfiram or placebo disulfiram according to their randomized assignments and are maintained on study medications through week 14 At the end of the study participants will undergo detoxification from the opioid agonist if relevant and activeplacebo medication over a 4- to 6-week period All participants receive weekly 1-hour psychotherapy Cognitive Behavioral Treatment with experienced clinicians specifically trained to deliver the therapy and who will receive ongoing supervision Participants undergo a delay discounting session during week 1 The primary outcomes will be retention reduction in opioid and cocaine use as assessed by self-report and confirmed by thrice-weekly urinalyses and disulfiram side-effects profile Secondary outcomes will include reductions in other illicit drug and alcohol use and improvements in psychosocial functioning The prognostic relevance of genotype at the DBH locus DβH activity etc on response to disulfiram will be examined
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 5R01DA013441-02 | NIH | None | None |
| 5R01DA013441-03 | NIH | None | None |
| 5R01DA013441-04 | NIH | None | None |
| 5R01DA013441-06 | NIH | None | None |
| 1R01DA013441-01A1 | NIH | None | None |
| 7R01DA013441-05 | NIH | None | None |
| 5R01DA013441-09 | NIH | None | None |
| 5R01DA013441-10 | NIH | None | None |
| 5R01DA013441-08 | NIH | None | None |
| R01DA013441 | NIH | None | None |
| DPMC | OTHER | NIDA | httpsreporternihgovquickSearchR01DA013441 |